GlassScriptPhysician profile
Mark Kevin Bryant
NPI 1093939746
$1,881.42
in general payments reported to CMS, 2019-2025
9 companies · $1,637 in 2025
The $1,637 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.13 · 2021: $43.08 · 2022: $71.45 · 2023: $34.68 · 2025: $1,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,500 · Food and Beverage: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,500.00 |
| Food and Beverage | $171.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $1,500.00 | 2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Alcon Vision LLC | $121.74 | 2019-2022 | |
| Coopervision INC. | $74.07 | 2019 | |
| Sun Pharmaceutical Industries INC. | $60.77 | 2025 | |
| Oyster Point Pharma, INC. | $34.68 | 2023 | Tyrvaya |
| Genentech USA, INC. | $32.23 | 2025 | Vabysmo |
| Mallinckrodt Hospital Products INC. | $25.90 | 2025 | Acthar |
| Bausch & Lomb Americas INC. | $18.18 | 2025 | Miebo |
| Abbvie INC. | $13.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bryant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.